Effects of tolvaptan on dyspnoea relief from the EVEREST trials

Peter Pang, Marvin A. Konstam, Holly B. Krasa, Karl Swedberg, Faiez Zannad, John E A Blair, Christopher Zimmer, John R. Teerlink, Aldo P. Maggioni, John C. Burnett, Liliana Grinfeld, John Ouyang, James E. Udelson, Mihai Gheorghiade

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

AimsTo describe the effects of tolvaptan therapy on dyspnoea relief based on timing of delivery, influence of concomitant therapies, and baseline patient and clinical characteristics. Also, the influence of clinical trial design on dyspnoea measurement, from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trials.Methods and resultsPost hoc analysis was performed based on the endpoint of patient-assessed dyspnoea. Changes from baseline at inpatient Day 1 were compared between treatment groups by the van Elteren test. Pre-determined subgroup analyses were also performed. Tolvaptan's effects are greatest within 12 h after first dose with an additional, but modest dyspnoea improvement benefit irrespective of time after admission. Overall, patients continue to report dyspnoea improvement up to 60 h after admission. The window of enrolment, up to 48 h after admission, combined with measurement on 'Day 1' led to a wide range over when dyspnoea was assessed.ConclusionPost hoc analysis suggests that tolvaptan modestly improves dyspnoea compared with standard therapy alone, regardless if given early or relatively late after hospitalization, and also across major pre-specified subgroups, despite ongoing background therapy aimed at relieving signs and symptoms. Significant variability around when dyspnoea was assessed, in addition to the persistence of dyspnoea despite ongoing background therapy, may influence how future clinical trials assess dyspnoea in acute heart failure syndromes.

Original languageEnglish (US)
Pages (from-to)2233-2240
Number of pages8
JournalEuropean Heart Journal
Volume30
Issue number18
DOIs
StatePublished - Sep 2009
Externally publishedYes

Fingerprint

Dyspnea
Therapeutics
Heart Failure
tolvaptan
Clinical Trials
Vasopressins
Signs and Symptoms
Inpatients
Hospitalization
Outcome Assessment (Health Care)

Keywords

  • Acute heart failure syndromes
  • Clinical trials
  • Dyspnoea
  • Heart failure
  • Vasopressin antagonists

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Pang, P., Konstam, M. A., Krasa, H. B., Swedberg, K., Zannad, F., Blair, J. E. A., ... Gheorghiade, M. (2009). Effects of tolvaptan on dyspnoea relief from the EVEREST trials. European Heart Journal, 30(18), 2233-2240. https://doi.org/10.1093/eurheartj/ehp253

Effects of tolvaptan on dyspnoea relief from the EVEREST trials. / Pang, Peter; Konstam, Marvin A.; Krasa, Holly B.; Swedberg, Karl; Zannad, Faiez; Blair, John E A; Zimmer, Christopher; Teerlink, John R.; Maggioni, Aldo P.; Burnett, John C.; Grinfeld, Liliana; Ouyang, John; Udelson, James E.; Gheorghiade, Mihai.

In: European Heart Journal, Vol. 30, No. 18, 09.2009, p. 2233-2240.

Research output: Contribution to journalArticle

Pang, P, Konstam, MA, Krasa, HB, Swedberg, K, Zannad, F, Blair, JEA, Zimmer, C, Teerlink, JR, Maggioni, AP, Burnett, JC, Grinfeld, L, Ouyang, J, Udelson, JE & Gheorghiade, M 2009, 'Effects of tolvaptan on dyspnoea relief from the EVEREST trials', European Heart Journal, vol. 30, no. 18, pp. 2233-2240. https://doi.org/10.1093/eurheartj/ehp253
Pang P, Konstam MA, Krasa HB, Swedberg K, Zannad F, Blair JEA et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. European Heart Journal. 2009 Sep;30(18):2233-2240. https://doi.org/10.1093/eurheartj/ehp253
Pang, Peter ; Konstam, Marvin A. ; Krasa, Holly B. ; Swedberg, Karl ; Zannad, Faiez ; Blair, John E A ; Zimmer, Christopher ; Teerlink, John R. ; Maggioni, Aldo P. ; Burnett, John C. ; Grinfeld, Liliana ; Ouyang, John ; Udelson, James E. ; Gheorghiade, Mihai. / Effects of tolvaptan on dyspnoea relief from the EVEREST trials. In: European Heart Journal. 2009 ; Vol. 30, No. 18. pp. 2233-2240.
@article{10f5903ec4e14b539541721e485d41f8,
title = "Effects of tolvaptan on dyspnoea relief from the EVEREST trials",
abstract = "AimsTo describe the effects of tolvaptan therapy on dyspnoea relief based on timing of delivery, influence of concomitant therapies, and baseline patient and clinical characteristics. Also, the influence of clinical trial design on dyspnoea measurement, from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trials.Methods and resultsPost hoc analysis was performed based on the endpoint of patient-assessed dyspnoea. Changes from baseline at inpatient Day 1 were compared between treatment groups by the van Elteren test. Pre-determined subgroup analyses were also performed. Tolvaptan's effects are greatest within 12 h after first dose with an additional, but modest dyspnoea improvement benefit irrespective of time after admission. Overall, patients continue to report dyspnoea improvement up to 60 h after admission. The window of enrolment, up to 48 h after admission, combined with measurement on 'Day 1' led to a wide range over when dyspnoea was assessed.ConclusionPost hoc analysis suggests that tolvaptan modestly improves dyspnoea compared with standard therapy alone, regardless if given early or relatively late after hospitalization, and also across major pre-specified subgroups, despite ongoing background therapy aimed at relieving signs and symptoms. Significant variability around when dyspnoea was assessed, in addition to the persistence of dyspnoea despite ongoing background therapy, may influence how future clinical trials assess dyspnoea in acute heart failure syndromes.",
keywords = "Acute heart failure syndromes, Clinical trials, Dyspnoea, Heart failure, Vasopressin antagonists",
author = "Peter Pang and Konstam, {Marvin A.} and Krasa, {Holly B.} and Karl Swedberg and Faiez Zannad and Blair, {John E A} and Christopher Zimmer and Teerlink, {John R.} and Maggioni, {Aldo P.} and Burnett, {John C.} and Liliana Grinfeld and John Ouyang and Udelson, {James E.} and Mihai Gheorghiade",
year = "2009",
month = "9",
doi = "10.1093/eurheartj/ehp253",
language = "English (US)",
volume = "30",
pages = "2233--2240",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "18",

}

TY - JOUR

T1 - Effects of tolvaptan on dyspnoea relief from the EVEREST trials

AU - Pang, Peter

AU - Konstam, Marvin A.

AU - Krasa, Holly B.

AU - Swedberg, Karl

AU - Zannad, Faiez

AU - Blair, John E A

AU - Zimmer, Christopher

AU - Teerlink, John R.

AU - Maggioni, Aldo P.

AU - Burnett, John C.

AU - Grinfeld, Liliana

AU - Ouyang, John

AU - Udelson, James E.

AU - Gheorghiade, Mihai

PY - 2009/9

Y1 - 2009/9

N2 - AimsTo describe the effects of tolvaptan therapy on dyspnoea relief based on timing of delivery, influence of concomitant therapies, and baseline patient and clinical characteristics. Also, the influence of clinical trial design on dyspnoea measurement, from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trials.Methods and resultsPost hoc analysis was performed based on the endpoint of patient-assessed dyspnoea. Changes from baseline at inpatient Day 1 were compared between treatment groups by the van Elteren test. Pre-determined subgroup analyses were also performed. Tolvaptan's effects are greatest within 12 h after first dose with an additional, but modest dyspnoea improvement benefit irrespective of time after admission. Overall, patients continue to report dyspnoea improvement up to 60 h after admission. The window of enrolment, up to 48 h after admission, combined with measurement on 'Day 1' led to a wide range over when dyspnoea was assessed.ConclusionPost hoc analysis suggests that tolvaptan modestly improves dyspnoea compared with standard therapy alone, regardless if given early or relatively late after hospitalization, and also across major pre-specified subgroups, despite ongoing background therapy aimed at relieving signs and symptoms. Significant variability around when dyspnoea was assessed, in addition to the persistence of dyspnoea despite ongoing background therapy, may influence how future clinical trials assess dyspnoea in acute heart failure syndromes.

AB - AimsTo describe the effects of tolvaptan therapy on dyspnoea relief based on timing of delivery, influence of concomitant therapies, and baseline patient and clinical characteristics. Also, the influence of clinical trial design on dyspnoea measurement, from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trials.Methods and resultsPost hoc analysis was performed based on the endpoint of patient-assessed dyspnoea. Changes from baseline at inpatient Day 1 were compared between treatment groups by the van Elteren test. Pre-determined subgroup analyses were also performed. Tolvaptan's effects are greatest within 12 h after first dose with an additional, but modest dyspnoea improvement benefit irrespective of time after admission. Overall, patients continue to report dyspnoea improvement up to 60 h after admission. The window of enrolment, up to 48 h after admission, combined with measurement on 'Day 1' led to a wide range over when dyspnoea was assessed.ConclusionPost hoc analysis suggests that tolvaptan modestly improves dyspnoea compared with standard therapy alone, regardless if given early or relatively late after hospitalization, and also across major pre-specified subgroups, despite ongoing background therapy aimed at relieving signs and symptoms. Significant variability around when dyspnoea was assessed, in addition to the persistence of dyspnoea despite ongoing background therapy, may influence how future clinical trials assess dyspnoea in acute heart failure syndromes.

KW - Acute heart failure syndromes

KW - Clinical trials

KW - Dyspnoea

KW - Heart failure

KW - Vasopressin antagonists

UR - http://www.scopus.com/inward/record.url?scp=70349464874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349464874&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehp253

DO - 10.1093/eurheartj/ehp253

M3 - Article

VL - 30

SP - 2233

EP - 2240

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 18

ER -